Vincerx Pharma, Inc. stock is up 257.14% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 March’s closed higher than February.
Vincerx Pharma, Inc. researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!